The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Unfortunately no one is estimating how long the approval of health claims will take and even Liu Hongyu, the SAMR guy in the article only says "judging from the current procedures drafted in the "Implementation Rules", new function suggestions and new product registration are "two-in-one" procedures, with the purpose of benefiting approved companies as quickly as possible"
With the exception of maybe SAMR and possibly By-Health I doubt anyone knows of possible timescales.
Https://www-ebrun-com.translate.goog/20231218/537182.shtml?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
As for funding... I believe, and correct me if I am wrong, its a requirement (Going Concern) to say funds may be needed up until we have enough cash in the bank for over 12 months operation from the date of the financial results.
Hopefully we can make enough profit to cover this without a fund raise but who knows.
I don't see it as "wishful thinking" BB
In fact, for a company our size I would be surprised if IF didn't go PIA (Payment in advance) and, as you know, it was reported on ADVFN from someone who attended the AGM that "It was explained that IF had insisted on payment up front from all DSM customers which had been accepted in every case thus adding no additional pressure on Cash Flow." although it would be good to have this confirmed in the interims.
This is a good situation while we can draw down on the stock that DSM hold but I would expect we would need serious cash in the bank when ordering new stock.
Could By-Health also be PIA? I have no idea what the lead time is to produce new stock but they could be and they cant get it anywhere else.
Krusty, best thing to do if you have any concerns about interactions with your statins is to contact the company.
https://www.fruitflowplus.com/contact-us/
The health benefit conferred by WSTE may be one that directly impacts on the digestive system. For instance, WSTE may benefit a subject in at least one of the following ways:
(A) improving digestion;
(B) improving resistance to infection in the gut;
(C) reducing inflammation in the gut;
(D)treating or minimising inflammatory Bowel Disease (IBD); or
(E) treating or minimising irritable bowel syndrome (IBS).
Alternatively, the health benefit conferred by WSTE may be to address conditions whose pathology is caused or aggravated by compounds released by the gut microbiota into the bloodstream and whereby WSTE modulates plasma levels of such compounds by modulating the gut microbiota. For instance, WSTE also benefits a subject by:
(A) treating or preventing anxiety and/or depression;
(B) treating or preventing Type II diabetes;
(C) treating or preventing non-alcoholic fatty liver disease;
(D) Treating or preventing obesity;
(E) preventing or reducing inflammaging (or inflamm-aging);
(F) Immune disorders; and
(G) Improving or maintaining cognitive function and brain health.
Https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023237878&_cid=P12-LQ68ZU-24723-1
COMPOSITIONS FOR TREATING IMBALANCES OF THE GUT MICROBIOTA
Publication Date 14.12.2023
"The tomato extract can be used improve resistance to infection in the gut, reduce inflammation in the gut, treat or minimise inflammatory Bowel Disease or treat or minimise irritable bowel syndrome. The extracts may also be used to treat conditions associated with an imbalance of the gut microbiota such as anxiety, depression, Type II diabetes, non-alcoholic fatty liver disease, obesity or cognitive dysfunction."
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023237878&_cid=P12-LQ6875-04787-1